Set Analyses:
Advanced Search

Advanced Search

 
Search By
Section (entire)
for


Category   Symbol Source: HGNC EntrezGene Ensembl
GIFtS

Search by expression pattern Search by expression pattern



HLA-DRB1 Gene

protein-coding   GIFtS: 64

GC06M032546
major histocompatibility complex, class II, DR beta 1
Symbol approved by the HUGO Gene Nomenclature Committee (HGNC) database
(Previous symbol: HLA-DR1B)
Products    

(According to 1HGNC, 2Entrez Gene,
3UniProtKB/Swiss-Prot, 4UniProtKB/TrEMBL, 5OMIM, 6GeneLoc , and/or 7Ensembl, 8miRBase)
About This Section

Aliases & Descriptions
major histocompatibility complex, class II, DR beta 11 2     DR-143
DRw112 3     MHC class II antigen DRB1*163
DR12 3     MHC class II antigen DRB1*83
DR52 3     MHC class II antigen DRB1*113
DRw82 3     DR133
DRw102 3     DW2.2/DR2.23
DR82 3     DR43
DR-162 3     DR73
DR162 3     MHC class II antigen DRB1*73
DR-82 3     DR-133
HLA-DR1B2 5     MHC class II antigen DRB1*103
SS12 5     MHC class II antigen DRB1*33
MHC class II HLA-DR beta 1 chain2     DR-123
MHC class II HLA-DRw10-beta2     DR143
human leucocyte antigen DRB12     MHC class II antigen DRB1*43
HLA class II histocompatibility antigen, DR-1 beta chain2     DR-53
leucocyte antigen DRB12     DR123
DRB12     MHC class II antigen DRB1*153
FLJ750172     HLA-DRB23
HLA class II antigen beta chain2     DR-43
lymphocyte antigen DRB12     DR-73
MHC class II antigen HLA-DR132     DR93
HLA-DRB1*2     DR-93
FLJ763592     MHC class II antigen DRB1*133
HLA-DRB2     MHC class II antigen DRB1*123
leucocyte antigen DR beta 1 chain2     DR-13
HLA-DR-beta 12     MHC class II antigen DRB1*143
MHC class II HLA-DR-beta cell surface glycoprotein2     Clone P2-beta-33
MHC class II antigen DRB1*13     MHC class II antigen DRB1*93

External Ids:    HGNC: 49481   Entrez Gene: 31232   Ensembl: ENSG000001961267   UniProtKB: P042293   UniProtKB: P019123   
UniProtKB: P137603   UniProtKB: P137613   UniProtKB: Q301343   UniProtKB: Q9TQE03   UniProtKB: Q301673   
UniProtKB: P200393   UniProtKB: Q95IE33   UniProtKB: Q5Y7A73   UniProtKB: Q9GIY33   UniProtKB: P019113   
UniProtKB: Q299743   

Export aliases for HLA-DRB1 gene to outside databases

Previous GC identifers: GC06U990049 GC06Md32547 GC06M032317 GC06Md32654 GC06M032656


(According to Entrez Gene, Tocris Bioscience, Wikipedia's Gene Wiki,
UniProtKB/Swiss-Prot, and/or UniProtKB/TrEMBL)
About This Section

Entrez Gene summary for HLA-DRB1:
HLA-DRB1 belongs to the HLA class II beta chain paralogs. The class II molecule is a heterodimer consisting of an alpha
(DRA) and a beta chain (DRB), both anchored in the membrane. It plays a central role in the immune system by
presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells
(APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa. It is encoded by 6
exons. Exon one encodes the leader peptide; exons 2 and 3 encode the two extracellular domains; exon 4 encodes the
transmembrane domain; and exon 5 encodes the cytoplasmic tail. Within the DR molecule the beta chain contains all the
polymorphisms specifying the peptide binding specificities. Hundreds of DRB1 alleles have been described and typing
for these polymorphisms is routinely done for bone marrow and kidney transplantation. DRB1 is expressed at a level
five times higher than its paralogs DRB3, DRB4 and DRB5. DRB1 is present in all individuals. Allelic variants of DRB1
are linked with either none or one of the genes DRB3, DRB4 and DRB5. There are 4 related pseudogenes: DRB2, DRB6,
DRB7, DRB8 and DRB9. (provided by RefSeq)

UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974
Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous
antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and
for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition
to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74
and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a
small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by
HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and
efficient peptide loading

Gene Wiki entry for HLA-DRB1

(According to GeneLoc and/or HGNC, and/or
Entrez Gene (NCBI build 37),
and/or miRBase,
Genomic Views according to UCSC (hg19) and Ensembl (release 60), Regulatory elements and Epigenetics data according to Qiagen and/or SABiosciences)
About This Section

Regulatory elements:
   SABiosciences Regulatory transcription factor binding sites in the HLA-DRB1 gene promoter:
         NF-kappaB1   NF-kappaB   CUTL1   c-Rel   POU3F1   RelA   C/EBPbeta   LCR-F1   CP1C   NF-Y   
         Other transcription factors

   Search SABiosciences Chromatin IP Primers for HLA-DRB1

Epigenetics:
QIAGEN PyroMark CpG Assay predesigned Pyrosequencing DNA Methylation assays 


Genomic Location:
Genomic View: UCSC Golden Path with GeneCards custom track

Entrez Gene cytogenetic band: 6p21.3   Ensembl cytogenetic band:  6p21.32   HGNC cytogenetic band: 6p21.3

HLA-DRB1 Gene in genomic location: bands according to Ensembl, locations according to (and/or Entrez Gene and/or Ensembl if different)
HLA-DRB1 gene location

GeneLoc gene densities for chromosome 6         GeneLoc Exon Structure

GeneLoc location for GC06M032546:  view genomic region     (about GC identifiers)

Start:
32,546,546 bp from pter
End:
32,578,053 bp from pter
Size:
31,508 bases
Orientation:
minus strand

2 alternative locations:
Chr6-,ALT_REF_LOCI_2 32,515,135-32,528,486      Chr6-,ALT_REF_LOCI_7 32,567,891-32,582,577     
RefSeq DNA sequence:
NC_000006.11  NT_007592.15  NT_113891.2  NT_167249.1  

(According to 1UniProtKB, neXtProt, and/or Ensembl, Phosphorylation sites according to 2Phosphosite, RefSeq according to NCBI, PDB rendering according to OCA and/or Proteopedia, Recombinant Proteins from Millipore, Sigma-Aldrich, R&D Systems, GenScript, Enzo Life Sciences, OriGene, Novus Biologicals, Sino Biological, and/or ProSpec,
Biochemical Assays by Millipore, Sigma-Aldrich, R&D Systems, OriGene, GenScript, Cell Signaling Technology, Enzo Life Sciences, and/or Uscn, Ontologies according to Gene Ontology Consortium 01 Dec 2010 and Entrez Gene, Antibodies by Millipore, Sigma-Aldrich, R&D Systems, GenScript, Cell Signaling Technology, OriGene, Novus Biologicals, and/or Epitomics)
About This Section

UniProtKB/Swiss-Prot: 2B11_HUMAN, P04229 (See protein sequence)
Recommended Name: HLA class II histocompatibility antigen, DRB1-1 beta chain precursor  
Size: 266 amino acids; 29914 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
PDB structures from and Proteopedia :
1AQD (3D)    1DLH (3D)    1FYT (3D)    1HXY (3D)    1JWM (3D)    1JWS (3D)    1JWU (3D)    1KG0 (3D)    
1KLG (3D)    1KLU (3D)    1LO5 (3D)    1PYW (3D)    1R5I (3D)    1SEB (3D)    1SJE (3D)    1SJH (3D)    
1T5W (3D)    1T5X (3D)    2FSE (3D)    2G9H (3D)    2IAM (3D)    2IAN (3D)    2ICW (3D)    2IPK (3D)    
2OJE (3D)    3L6F (3D)    
Secondary accessions: A4F5N0 A8K098 O62869 P13758 Q06662 Q30116 Q30117 Q5Y7E9 Q7M2H4 Q95461 Q9BCL7
Q9GIK5 Q9MXZ0 Q9MXZ5 Q9TQ91

UniProtKB/Swiss-Prot: 2B13_HUMAN, P01912 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-3 chain precursor  
Size: 266 amino acids; 30120 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
PDB structures from and Proteopedia :
1A6A (3D)    

UniProtKB/Swiss-Prot: 2B14_HUMAN, P13760 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-4 beta chain precursor  
Size: 266 amino acids; 30112 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
PDB structures from and Proteopedia :
1D5M (3D)    1D5X (3D)    1D5Z (3D)    1D6E (3D)    1J8H (3D)    2SEB (3D)    
Secondary accessions: O19717 O19739 P13759 Q29875 Q30145 Q9GIX9 Q9GIY4 Q9MY13 Q9XRY5

UniProtKB/Swiss-Prot: 2B17_HUMAN, P13761 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-7 beta chain precursor  
Size: 266 amino acids; 29822 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions: B0UYW1 O46699 O46872

UniProtKB/Swiss-Prot: 2B18_HUMAN, Q30134 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-8 beta chain precursor  
Size: 266 amino acids; 30004 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions: O19718 O19788 Q29968 Q30108 Q30115 Q9BCP0 Q9BCP1 Q9BCP2 Q9BD33 Q9TQ37 Q9UIM9

UniProtKB/Swiss-Prot: 2B19_HUMAN, Q9TQE0 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-9 beta chain precursor  
Size: 266 amino acids; 29826 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions: Q30149

UniProtKB/Swiss-Prot: 2B1A_HUMAN, Q30167 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-10 beta chain precursor  
Size: 266 amino acids; 30002 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions: P01914 Q9MYF5

UniProtKB/Swiss-Prot: 2B1B_HUMAN, P20039 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-11 beta chain precursor  
Size: 266 amino acids; 30160 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions: Q30006 Q9GIX8

UniProtKB/Swiss-Prot: 2B1C_HUMAN, Q95IE3 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-12 beta chain precursor  
Size: 266 amino acids; 29878 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions: A7LA26 B0LUZ6 B6VCX2 B7UDB2 O19585 Q19AF2 Q29771 Q2L9H4 Q2MZ92 Q5EER6 Q5NDB9
Q5UT58 Q5Y7G0 Q768U4 Q7YP04 Q861H8 Q95IT6 Q9BD40

UniProtKB/Swiss-Prot: 2B1D_HUMAN, Q5Y7A7 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-13 beta chain precursor  
Size: 266 amino acids; 30008 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Sequence caution: Sequence=CAB40418.1; Type=Erroneous gene model prediction;
Secondary accessions: A0MWF2 A2ICT1 A4ZXA5 A4ZXA6 A7UHG2 A7X5K7 A8YQE9 B0BK85 B3VTQ3 B5A8Y2 B5A8Y3
B5B9V6 B5QSK8 C0LAB5 O02930 O62889 O78047 P79545 Q14280 Q14QT2 Q19K86 Q1G0Z9 Q1KLJ6 Q29673 Q29720
Q29722 Q29806 Q29833 Q29874 Q29886 Q2MF40 Q2YHQ2 Q30112 Q3LA93 Q3LA94 Q3LA95 Q3LA96 Q3LA97 Q3LA98
Q3LA99 Q3LAA0 Q3LAA1 Q3LAA2 Q3MQ60 Q53IG1 Q56FP2 Q56FP3 Q58F52 Q5K3W2 Q5UBA2 Q5W3L4 Q6REE2 Q6U387
Q701T1 Q70Q85 Q768U2 Q7YP03 Q7YQ26 Q7YQA3 Q860E5 Q860H8 Q860Z3 Q861G6 Q861H0 Q861H4 Q8HWQ6 Q8WMA0
Q95389 Q95HL1 Q96HZ9 Q9BCP5 Q9BD21 Q9GIP3 Q9GJ25 Q9GJ60 Q9GJF8 Q9GJF9 Q9GJG0 Q9MY45 Q9MY56 Q9TPW3
Q9TPW9 Q9TPX4 Q9UBY1 Q9UIN0 Q9XRX1 Q9Y453

UniProtKB/Swiss-Prot: 2B1E_HUMAN, Q9GIY3 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-14 beta chain precursor  
Size: 266 amino acids; 30139 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Sequence caution: Sequence=CAB45249.1; Type=Erroneous gene model prediction;
Secondary accessions: A0N0W1 A2TGX3 A4ZY86 A5H000 A5HKN8 A7DZP9 A7X5B1 A7X5B7 A7X5E0 A7X5E6 A7X5H8
A9JPG0 B1GWE7 B2CR03 B2LVF9 B2NJ29 B2ZCY1 B3VTP8 B5B8U0 B5B9V5 B5LZ25 B6VEL9 B9VRA4 B9X248 O02876
O46793 O77969 O78210 Q0PQ39 Q155F7 Q1AP33 Q1JRP3 Q27PR6 Q27PR7 Q29734 Q29770 Q29772 Q29800 Q2A120
Q2HZE5 Q2LE76 Q2MJA6 Q2VQU1 Q307W5 Q31636 Q3LA87 Q3LA88 Q3LA89 Q3LA90 Q3LA91 Q3LA92 Q3T919 Q4PRC3
Q4PRC5 Q4VZY7 Q56FP1 Q5BM92 Q5U9W6 Q683P7 Q70GL2 Q7YNY9 Q7YQA5 Q860D8 Q860D9 Q860S0 Q861H5 Q861H7
Q8MH59 Q8MH60 Q8WLU3 Q95348 Q95HK1 Q95HL0 Q95IG2 Q9GIL5 Q9GIL6 Q9GIY0 Q9GIY1 Q9GIY2 Q9GJ56 Q9GJ57
Q9GJ58 Q9TPB6 Q9TPW1 Q9XRY4 Q9Y4H7

UniProtKB/Swiss-Prot: 2B1F_HUMAN, P01911 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-15 beta chain precursor  
Size: 266 amino acids; 29966 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Miscellaneous: The chain shown constituted about 70% of a pool of at least seven similar beta chains
PDB structures from and Proteopedia :
1BX2 (3D)    1YMM (3D)    2WBJ (3D)    
Secondary accessions: Q29790 Q29975 Q30142 Q30166 Q32MY7 Q56FN9 Q5Y7B0 Q5Y7B9

UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974 (See protein sequence)

Recommended Name: HLA class II histocompatibility antigen, DRB1-16 beta chain precursor  
Size: 266 amino acids; 30030 Da
Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic
reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant
chain or HLA class II histocompatibility antigen gamma chain). In the endosomal/lysosomal system; CD74 undergoes
sequential degradation by various proteases; leaving a small fragment termed CLIP on each MHC class II molecule. MHC
class II molecule interacts with HLA_DM, and HLA_DO in B cells, in order to release CLIP and facilitate the binding of
antigenic peptides
Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass
type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome
membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome
membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of
intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
Secondary accessions: A7X5J4 O98212 Q0PGR5 Q29792 Q30120 Q30159 Q30200 Q3HUP9 Q3KTM1 Q3LA84 Q6T865
Q95383

Explore the universe of human proteins at neXtProt for HLA-DRB1: NX_Q29974 

Post-translational modifications:

  • Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to sorting into the endosome system and down-regulation of MHC
  • class II (Probable)1
  • View phosphorylation sites using PhosphoSite2


  • REFSEQ proteins: NP_002115.2  

    ENSEMBL proteins: 
    ENSP00000353099 


    Human Recombinant Proteins 
    Browse Purified and Recombinant Proteins at Millipore
    Browse Human Recombinant Proteins at Sigma-Aldrich
    Browse R&D Systems for human recombinant proteins
    Browse recombinant and purified proteins available from Enzo Life Sciences
    Browse OriGene full length recombinant human proteins expressed in human HEK293 cells
    Browse OriGene Protein Over-expression Lysates
    GenScript Custom Purified and Recombinant Proteins Services for HLA-DRB1 
    Novus Biologicals Lysate for HLA-DRB1
    Browse Sino Biological Recombinant Proteins
    Browse ProSpec Recombinant Proteins

    5/11 Gene Ontology (GO) cellular component terms (GO ID links to tree view) (see all 11):

    GO IDQualified GO termEvidencePubMed IDs
    GO:0005765 lysosomal membrane IDA18305173
    GO:0005768 endosome IEA--
    GO:0005783 endoplasmic reticulum IEA--
    GO:0005789 endoplasmic reticulum membrane IEA--
    GO:0005794 Golgi apparatus IEA--
    About this table

    HLA-DRB1 for ontologies           About GeneDecksing



    Antibodies for HLA-DRB1: 
    Browse Millipore's Extensive Line of Mono- and Polyclonal Antibodies
    Sigma-Aldrich Antibodies for HLA-DRB1
    Browse R&D Systems for Antibodies
    Browse OriGene Antibodies
    GenScript Custom Superior Antibodies Services for HLA-DRB1 
    Novus Biologicals Antibodies for HLA-DRB1
    Epitomics antibodies for HLA-DRB1

    Assays for HLA-DRB1: 
    Browse Kits and Assays available from Millipore
    Browse ELISAs at Sigma-Aldrich
    OriGene Custom Immunoassay Development 
    Browse OriGene Fluorogenic Cell Assay Kits 
    Browse R&D Systems for biochemical assays
    GenScript Custom Assay Services for HLA-DRB1 
    Browse Enzo Life Sciences for kits & assays
    Uscn ELISAs and CLIAs for HLA-DRB1 


    (According to InterPro, ProtoNet, UniProtKB, and/or BLOCKS, Sets of similar genes according to GeneDecks)
    About This Section

    HLA-DRB1 for domains           About GeneDecksing

    5/7 InterPro domains/families (see all 7):
     IPR011162 MHC_I/II-like_Ag-recog
     IPR000353 MHC_II_b_N
     IPR013783 Ig-like_fold
     IPR014745 MHC_II_a/b_N
     IPR003597 Ig_C1-set

    Graphical View of Domain Structure for InterPro Entry P04229
    Graphical View of Domain Structure for InterPro Entry P01912
    Graphical View of Domain Structure for InterPro Entry P13760
    Graphical View of Domain Structure for InterPro Entry P13761
    Graphical View of Domain Structure for InterPro Entry Q30134
    Graphical View of Domain Structure for InterPro Entry Q9TQE0
    Graphical View of Domain Structure for InterPro Entry Q30167
    Graphical View of Domain Structure for InterPro Entry P20039
    Graphical View of Domain Structure for InterPro Entry Q95IE3
    Graphical View of Domain Structure for InterPro Entry Q5Y7A7
    Graphical View of Domain Structure for InterPro Entry Q9GIY3
    Graphical View of Domain Structure for InterPro Entry P01911
    Graphical View of Domain Structure for InterPro Entry Q29974

    ProtoNet protein and cluster: P04229

    2 Blocks protein families:
    IPB000353 Class II histocompatibility antigen
    IPB003597 Immunoglobulin C-type


    UniProtKB/Swiss-Prot: 2B11_HUMAN, P04229
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B13_HUMAN, P01912
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B14_HUMAN, P13760
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B17_HUMAN, P13761
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B18_HUMAN, Q30134
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B19_HUMAN, Q9TQE0
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B1A_HUMAN, Q30167
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B1B_HUMAN, P20039
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B1C_HUMAN, Q95IE3
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B1D_HUMAN, Q5Y7A7
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B1E_HUMAN, Q9GIY3
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B1F_HUMAN, P01911
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain

    UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974
    Similarity: Belongs to the MHC class II family
    Similarity: Contains 1 Ig-like C1-type (immunoglobulin-like) domain


    (According to UniProtKB, IUBMB,and/or Genatlas, Animal models from MGI Dec 24 2010,
    shRNA from OriGene, Sigma-Aldrich, RNAi from Millipore, siRNAs from Sigma-Aldrich, OriGene, Qiagen, Super-pooled esiRNAs from Sigma-Aldrich, microRNA from Sigma-Aldrich, Qiagen, SABiosciences, Clones from Millipore, Sigma-Aldrich, OriGene, GenScript, Sino Biological, Cell Lines from GenScript, Ontologies according to Gene Ontology Consortium 01 Dec 2010 via Entrez Gene.)
    About This Section

    UniProtKB/Swiss-Prot: 2B11_HUMAN, P04229
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74
    and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B13_HUMAN, P01912
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74
    and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B14_HUMAN, P13760
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74
    and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B17_HUMAN, P13761
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74
    and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B18_HUMAN, Q30134
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74
    and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B19_HUMAN, Q9TQE0
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74
    and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B1A_HUMAN, Q30167
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74
    and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells; the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B1B_HUMAN, P20039
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74
    and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B1C_HUMAN, Q95IE3
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74
    and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B1D_HUMAN, Q5Y7A7
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74
    and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B1E_HUMAN, Q9GIY3
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74
    and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B1F_HUMAN, P01911
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74
    and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and
    efficient peptide loading

    UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974
    Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and
    presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides
    of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins
    that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous
    antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and
    for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their
    way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal
    compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a
    source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition
    to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74
    and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an
    antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the
    ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen
    processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a
    small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM
    via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules
    until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported
    to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by
    HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the
    regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and
    efficient peptide loading

    Inhib.
    RNA:
        
    Browse for Gene Knock-down Tools from Millipore
    Browse Nano Scale siRNA at Sigma-Aldrich
    Sigma-Aldrich siRNA for HLA-DRB1
    Sigma-Aldrich shRNA Panels and shRNA for HLA-DRB1
    OriGene 29mer shRNA kits in GFP-retroviral vector (see all 5): HLA-DRB1
    OriGene shRNA RFP (see all 5): HLA-DRB1
    OriGene basic RS shRNA (see all 5): HLA-DRB1
    OriGene siRNA (see all 5): HLA-DRB1
    QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing of HLA-DRB1 
    miRNA:Sigma-Aldrich microRNA Mimics for HLA-DRB1
    Browse microRNA target validation systems at Sigma-Aldrich 
    QIAGEN Custom miScript Target Protector blocks miRNA-binding site of HLA-DRB1 
    Search SABiosciences for Assays for microRNAs that regulate HLA-DRB1

    Gene
    Editing:
    Browse CompoZr Knockout ZFN at Sigma-Aldrich 

    Clones:Browse Clones for the Expression of Recombinant Proteins Available from Millipore
    Browse iPSC Reprogramming Factors at Sigma-Aldrich
    OriGene GFP tagged cDNA clones in CMV expression vector: HLA-DRB1
    OriGene Myc/DDK tagged cDNA clones in CMV expression vector: HLA-DRB1
    OriGene untagged cDNA clones in CMV expression vector (see all 2): HLA-DRB1
    OriGene 3'-UTR clone: HLA-DRB1 
    Browse MicroRNA Expression Plasmids 
    GenScript Custom cDNA clone Services for HLA-DRB1 
    Browse Sino Biological Human cDNA Clones

    Cell
    Lines:
      
    GenScript Custom overexpressing Cell Line Services for HLA-DRB1 

    Genatlas biochemistry entry for HLA-DRB1:
    HLA-DR,beta 1 chain,determining DR1,3,4,5 etc

    2 Gene Ontology (GO) molecular function terms (GO ID links to tree view):

    GO IDQualified GO termEvidencePubMed IDs
    GO:0005515 protein binding IEA--
    GO:0032395 MHC class II receptor activity TAS3456344
    About this table

    HLA-DRB1 for ontologies           About GeneDecksing


    (Pathways according to Millipore, Cell Signaling Technology, Sigma-Aldrich, KEGG and/or UniProtKB, Sets of similar genes according to GeneDecks, PCR Arrays from SABiosciences, Proteins Network according to SABiosciences, Sigma-Aldrich, Interactions according to 1UniProtKB, 2MINT, and/or 3STRING, with links to IntAct and Ensembl, Ontologies according to Gene Ontology Consortium 01 Dec 2010 via Entrez Gene).
    About This Section


    HLA-DRB1 for pathways           About GeneDecksing

    5/6 Millipore Pathways for HLA-DRB1 (see all 6)
        Immune response Antigen presentation by MHC class II
    G-protein signaling N-RAS regulation pathway
    Immune response IL-22 signaling pathway
    Immune response NFAT in immune response
    Immune response ICOS pathway in T-helper cell

    5/22 Sigma-Aldrich "Your Favorite Gene" (powered by Ingenuity) Pathways for  HLA-DRB1 (see all 22)
        Antigen Presentation Pathway
    Calcium-induced T Lymphocyte Apoptosis
    Allograft Rejection Signaling
    B Cell Development
    Communication between Innate and Adaptive Immune Cells

    5/15 Kegg Pathways  (Kegg details for HLA-DRB1) (see all 15):
        hsa04145 Phagosome
    hsa04514 Cell adhesion molecules (CAMs)
    hsa04612 Antigen processing and presentation
    hsa04640 Hematopoietic cell lineage
    hsa04672 Intestinal immune network for IgA production

        SABiosciences Pathway-Focused PCR Array including HLA-DRB1: PAHS-3401A 

        Sigma-Aldrich "Your Favorite Gene" (powered by Ingenuity) Molecular Interaction Network for HLA-DRB1
        SABiosciences Gene Network CentralTM Interacting Genes and Proteins Network for HLA-DRB1

    5/61 Interacting proteins for HLA-DRB1 (P019122 P042292, 2 ENSP000003530993) via UniProtKB, MINT, and/or STRING (see all 61)
    InteractantInteraction Details
    GeneCardExternal ID(s)
    ENSG00000226260P019032MINT-24881
    ENSG00000228987P019032
    ENSG00000230726P019032
    ENSG00000234794P019032
    HLA-DRAP019032
    About this table

    5 Gene Ontology (GO) biological process terms (GO ID links to tree view):

    GO IDQualified GO termEvidencePubMed IDs
    GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II IEA--
    GO:0006955 immune response NAS3129499
    GO:0019882 antigen processing and presentation ----
    GO:0031295 T cell costimulation TAS--
    GO:0050852 T cell receptor signaling pathway TAS--
    About this table

    HLA-DRB1 for ontologies           About GeneDecksing



    (Chemical Compounds according to UniProtKB, Enzo Life Sciences, Sigma-Aldrich, Tocris Bioscience, and/or Novoseek and Drugs according to Enzo Life Sciences and/or PharmGKB)
    About This Section

    HLA-DRB1 for compounds           About GeneDecksing

    Browse Small Molecules at Sigma-Aldrich
    Browse drugs & compounds from Enzo Life Sciences

    Browse Tocris compounds for HLA-DRB1
    10/17 Novoseek chemical compound relationships for HLA-DRB1 gene (see all 17)
    Compound   -log (P-Val)   Hits   PubMed IDs for Articles with Shared Sentences (# sentences)
    dr-10 77.3 6 7780115 (1), 9550403 (1), 8754259 (1), 10626740 (1)
    dr-16 73.6 1 9243764 (1)
    dpa 1 73.1 5 8782076 (1), 8863870 (1), 17060025 (1), 10616003 (1) (see all 5)
    oligonucleotide 53.4 22 8117375 (1), 12823773 (1), 15865503 (1), 18718089 (1) (see all 20)
    gold sodium thiomalate 36 2 11093435 (1)
    valine 30.5 4 9098452 (1), 8500529 (1), 10439317 (1), 2369430 (1)
    amino acid 19.7 1 1533151 (1)
    c-peptide 4.17 1 15388265 (1)
    atp 3.36 2 12658812 (2)
    lysine 0 2 7738179 (1), 7612412 (1)
    About this table

    1 PharmGKB drug compound relationship for HLA-DRB1 gene
    Drug compound PharmGKB Relations PubMed IDs for articles supporting these relationships
    cyclosporinePD  9277043
    About this table



    (GenBank/EMBL/DDBJ Accessions according to
    Unigene (Build 228 Homo sapiens; Dec 8 2010) or GenBank,
    RefSeq according to Entrez Gene,
    DOTS (version 10), and/or AceView, transcript ids from Ensembl with links to UCSC,
    non coding RNAs according to RNAdb,
    ESTs according to GeneTide,
    exon structure from GeneLoc, alternative splicing isoforms according to ASD and/or ECgene,
    RNAi Products from Millipore,
    siRNAs from Sigma-Aldrich, OriGene, Qiagen, Super-pooled esiRNAs from Sigma-Aldrich,
    shRNA from Sigma-Aldrich, OriGene, microRNA from Sigma-Aldrich, Qiagen, SABiosciences,
    Tagged/untagged cDNA clones from OriGene, Sigma-Aldrich, GenScript, Primers from OriGene and/or SABiosciences)
    About This Section

    Inhib.
    RNA:
         
    Browse for Gene Knock-down Tools from Millipore
    Browse Nano Scale siRNA at Sigma-Aldrich
    Sigma-Aldrich siRNA for HLA-DRB1
    Sigma-Aldrich shRNA Panels and shRNA for HLA-DRB1
    OriGene 29mer shRNA kits in GFP-retroviral vector (see all 5): HLA-DRB1
    OriGene shRNA RFP (see all 5): HLA-DRB1
    OriGene basic RS shRNA (see all 5): HLA-DRB1
    OriGene siRNA (see all 5): HLA-DRB1
    QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing of HLA-DRB1 
    miRNA: Sigma-Aldrich microRNA Mimics for HLA-DRB1
    Browse microRNA target validation systems at Sigma-Aldrich 
    QIAGEN Custom miScript Target Protector blocks miRNA-binding site of HLA-DRB1 
    Search SABiosciences for Assays for microRNAs that regulate HLA-DRB1
    Clones: Browse FLAG tag genes at Sigma-Aldrich
    OriGene GFP tagged cDNA clones in CMV expression vector: HLA-DRB1
    OriGene Myc/DDK tagged cDNA clones in CMV expression vector: HLA-DRB1
    OriGene untagged cDNA clones in CMV expression vector (see all 2): HLA-DRB1
    OriGene 3'-UTR Clone: HLA-DRB1 
    Browse OriGene MicroRNA Expression Plasmids 
    GenScript Custom cDNA clone Services for HLA-DRB1 
    Primers: OriGene genome-wide validated SYBR primer pairs: HLA-DRB1
    Browse OriGene validated miRNA SYBR primer pairs 
    SABiosciences RT2 qPCR Primer Assay for HLA-DRB1: PPH65871A

    REFSEQ mRNAs for HLA-DRB1 gene: 

    NM_002124.2  

    Additional cDNA sequence: 

    AF000448.1 AF010142.1 AF017439.1 AF017440.1 AF017441.1 AF048707.1 AF192258.1 AF192259.1 
    AF199236.2 AF291675.1 AF361548.1 AF361549.1 AF436097.1 AF522251.1 AJ245881.1 AJ297583.1 
    AJ297584.1 AJ297585.1 AJ297586.2 AJ297587.1 AJ302075.1 AJ536121.1 AJ697892.1 AJ697893.1 
    AK225683.1 AK225690.1 AK226043.1 AK226058.1 AK289463.1 AK291499.1 AK291987.1 AK292151.1 
    AK293020.1 AM056024.1 AY052550.1 AY054375.1 AY138123.1 AY626551.1 AY626552.1 AY770514.1 
    AY935719.1 AY961062.1 AY961063.1 AY961064.1 AY961065.1 AY961066.1 AY961067.1 AY961068.1 
    AY961069.1 AY961070.2 AY961071.2 AY961072.1 AY961073.1 AY961074.1 AY961075.1 AY961076.1 
    AY961077.1 AY961078.1 BC001023.2 BC005312.1 BC007920.2 BC008403.1 BC008987.1 BC018832.2 
    BC018834.2 BC018835.2 BC024269.1 BC031023.1 BC033827.1 BC106057.1 BC108922.1 BC171883.1 
    CR592036.1 CR600239.1 CR601907.1 CR603301.1 CR603446.1 CR609601.1 CR609994.1 CR610561.1 
    CR613356.1 CR625333.1 DQ002917.1 DQ090958.1 DQ140279.1 DQ284431.1 DQ284432.1 DQ284433.1 
    DQ284435.1 EU375850.1 FJ200455.1 GQ891550.1 GQ891551.1 HM067843.1 HM067844.1 HM067845.1 
    HM067846.1 HM067847.1 HM067848.1 HM067849.1 HM067850.1 HM067851.1 HM067852.1 HM067853.1 
    HM067854.1 HM067855.1 HM067856.1 HM067857.1 HM067858.1 HM067859.1 HM067860.1 HM067861.1 
    HM067862.1 HM067863.1 L02545.1 L42143.1 L76133.1 M11161.1 M11867.1 M14191.1 
    M14661.1 M14662.1 M15068.1 M15179.1 M16731.1 M16941.1 M16942.1 M16957.1 
    M16958.1 M16959.1 M17378.1 M17380.1 M17381.1 M17385.1 M20138.1 M20430.1 
    M20504.1 M21008.1 M25265.1 M26038.1 M27126.1 M27635.1 M28583.1 M28584.1 
    M28991.1 M28992.1 M30179.1 M30180.1 M33600.1 M35980.1 M35981.1 M35982.1 
    M59803.1 S79787.1 U09201.1 U17379.1 U35375.1 U35729.1 U37433.1 U37582.1 
    U56640.1 U65585.1 U66825.1 U70544.1 U83583.1 U83584.1 U84892.1 U95817.1 
    U95819.1 U95820.1 U95989.1 V00522.1 X00699.1 X00700.1 X02902.1 X03069.1 
    X12544.1 X99896.1 

    24/72 DOTS entries (see all 72):

    DT.92410344  DT.91706875  DT.92028787  DT.95164729  DT.100776434  DT.92047682  DT.95164752  DT.92382901 
    DT.95164731  DT.121314547  DT.87079048  DT.40115364  DT.100781798  DT.100778733  DT.100650571  DT.100766538 
    DT.92380890  DT.121314746  DT.121314807  DT.97857272  DT.95230813  DT.92467723  DT.95164743  DT.91802323 

    24/89 AceView cDNA sequences (see all 89):

    M16731 BV201637 M17381 AJ536121 BC024269 AJ297586 AF291675 L42143 
    BV207240 AH002891 AJ245881 BV207185 M15073 BV183568 X02902 BV183567 
    M15069 BV207036 X12544 BV200472 U84892 BV200461 BV207215 BV207191 

    highest scoring ESTs for HLA-DRB1:

    AJ011065 AU099634 AY626552 AY770514 BC108922 BF976113 BI761102 BM770494 BQ066389 CD102759 

    Unigene Clusters for HLA-DRB1:

    Major histocompatibility complex, class II, DR beta 1
    Hs.534322  [show with all ESTs], Hs.696211  [show with all ESTs]
    Unigene Representative Sequences: AK290388, AK225690


    GeneLoc Exon Structure

    2 Ensembl transcripts including schematic representations, and UCSC links where relevant:
    ENST00000360004(uc011dqb.1 uc011dqa.1 uc011dqc.1 uc003obp.3)
    ENST00000480500

    (Experimental results according to 1GeneNote and GNF BioGPS,
    probe sets-to-genes annotations according to 2GeneAnnot , 3GeneTide , Sets of similar genes according to GeneDecks, Electronic Northern calculations according to data from UniGene (Build 228 Homo sapiens), SAGE tags according to CGAP, plus additional links to SOURCE, and/or GNF BioGPS, and/or EXPOLDB, and/or UniProtKB,
    Primers from OriGene and/or SABiosciences )
    About This Section

    HLA-DRB1 expression in normal and diseased human tissues

    1  / 2  / 3

    10 probe-sets matching HLA-DRB1 gene

    Affymetrix
    probe-set
    Array  GeneAnnot data GeneNote data GeneTide data
    # genes Sensitivity Specificity Correlation Length Gb_Accession Consensus Uniqueness Score Rank
    41723_s_at2, 3 U95-A 19 1.00 0.10 0.98 0.81 M32578 0.60 0.33 0.48 2
    75284_f_at2, 3 U95-D 9 0.88 0.45 0.98 1.19 T88824 0.40 0.44 0.42 1
    209312_x_at2, 3 U133-A 15 1.00 0.16 -- -- U65585 0.40 0.50 0.45 1
    215193_x_at2, 3 U133-A 23 1.00 0.13 -- -- AJ297586 0.40 0.67 0.55 1
    204670_x_at2, 3 U133-A 11 0.91 0.26 -- -- NM_002125 0.40 0.50 0.45 1
    208306_x_at2, 3 U133-A 11 0.64 0.14 -- -- NM_021983 0.20 0.50 0.38 1
    209312_x_at2 U133Plus2 15 1.00 0.16 -- -- -- -- -- -- --
    215193_x_at2 U133Plus2 23 1.00 0.13 -- -- -- -- -- -- --
    204670_x_at2 U133Plus2 11 0.91 0.26 -- -- -- -- -- -- --
    208306_x_at2 U133Plus2 11 0.64 0.14 -- -- -- -- -- -- --
    About this table

    HLA-DRB1 for expression           About GeneDecksing

    Data from Genenote  (Publications) and GNF BioGPS
        About these images
    HLA-DRB1 gene expression
    HLA-DRB1 gene electronic northern expression
    HLA-DRB1 gene sage expression
    About these images

    CGAP SAGE TAG: CATCTGTACT GAGTTAAAAA

    SOURCE GeneReport for Unigene clusters: Hs.534322 Hs.696211
    Primers: OriGene genome-wide validated SYBR primer pairs: HLA-DRB1
    Browse OriGene validated miRNA SYBR primer pairs 
    SABiosciences RT2 qPCR Primer Assay for HLA-DRB1: PPH65871A
        SABiosciences Expression via Pathway-Focused PCR Array including HLA-DRB1: PAHS-3401A 


    (Orthologs according to 1,2HomoloGene (2older version, for species not in 1newer version), 3euGenes, 4SGD and/or 5MGI Dec 24 2010, with possible further links to Flybase and/or WormBase, Gene Trees according to Ensembl)
    About This Section

    Orthologs for HLA-DRB1 gene from 5/7 species (see all 7)
    Organism Gene Locus Description Human
    Similarity
    NCBI accessions
    dog
    (Canis familiaris)
    DLA-DRB11   -- MHC class II DLA DRB1 beta chain 86.09(n)
    79.7(a)
    474860  NM_001014768.1  NP_001014768.1 
    cow
    (Bos taurus)
    BoLA-DRB31   -- major histocompatibility complex, class II, DRB3 85.96(n)
    78.57(a)
    282530  NM_001012680.2  NP_001012698.2 
    rat
    (Rattus norvegicus)
    RT1-Db11   -- RT1 class II, locus Db1 79.64(n)
    73.54(a)
    294270  NM_001008884.1  NP_001008884.1 
    mouse
    (Mus musculus)
    H2-Eb11 , 5 17 (17.98 cM)5
    histocompatibility 2, class II antigen E beta1, 5 81.48(n)1
    76.25(a)1
    149691  NM_010382.21  NP_034512.21 
     AF0501575  AK1559685  (see all 31)
    chicken
    (Gallus gallus)
    BLB11   -- MHC class II antigen B-F minor heavy chain 63.24(n)
    53.75(a)
    724083  NM_001044694.1  NP_001038159.1 
    About this table        Species with no ortholog for HLA-DRB1

    ENSEMBL Gene Tree for HLA-DRB1 (if available)

    (Paralogs according to 1HomoloGene
    and 2Ensembl, Pseudogenes according to 3Pseudogene.org)
    About This Section
    Paralogs for HLA-DRB1 gene
    HLA-DQB22  HLA-DRB52  ENSG000002489932  HLA-DQB12  HLA-DPB22  HLA-DMB2  HLA-DOB2  HLA-DPB12  

    HLA-DRB1 for paralogs           About GeneDecksing



    (SNPs according to the 1NCBI SNP Database, 2Ensembl, 3PupaSUITE, and UniProtKB, Linkage Disequilibrium by HapMap, Structural Variations(CNVs/InDels/Inversions) from the Database of Genomic Variants, Resequencing Primers from Qiagen)
    About This Section

    UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974
    Polymorphism: The following alleles of DRB1-1 are known: DRB1*01:01; DRB1*01:02; DRB1*01:03; DRB1*01:04; DRB1*01:05;
    DRB1*01:06; DRB1*01:07; DRB1*01:08; DRB1*01:09; DRB1*01:10; DRB1*01:11; DRB1*01:12; DRB1*01:13; DRB1*01:14;
    DRB1*01:15; DRB1*01:16; DRB1*01:17; DRB1*01:18; DRB1*01:19; DRB1*01:20 and DRB1*01:21. The sequence shown is that of
    DRB1*01:01
    Polymorphism: The following alleles of DRB1-3 are known: DRB1*03:01; DRB1*03:02; DRB1*03:03; DRB1*03:04; DRB1*03:05;
    DRB1*03:06; DRB1*03:07; DRB1*03:08; DRB1*03:09; DRB1*03:10; DRB1*03:11; DRB1*03:12; DRB1*03:13; DRB1*03:14;
    DRB1*03:15; DRB1*03:16; DRB1*03:17; DRB1*03:18; DRB1*03:19; DRB1*03:20; DRB1*03:21; DRB1*03:22; DRB1*03:23;
    DRB1*03:24; DRB1*03:25; DRB1*03:26; DRB1*03:27; DRB1*03:28; DRB1*03:29; DRB1*03:30; DRB1*03:31; DRB1*03:32;
    DRB1*03:33; DRB1*03:34; DRB1*03:35; DRB1*03:36; DRB1*03:37; DRB1*03:38; DRB1*03:39; DRB1*03:40 and DRB1*03:41. The
    sequence shown is that of DRB1*03:01
    Polymorphism: The following alleles of DRB1-4 are known: DRB1*04:01, DRB1*04:02, DRB1*04:03, DRB1*04:04, DRB1*04:05,
    DRB1*04:06, DRB1*04:07, DRB1*04:08, DRB1*04:09, DRB1*04:10, DRB1*04:11, DRB1*04:12, DRB1*04:13, DRB1*04:14,
    DRB1*04:15, DRB1*04:16, DRB1*04:17, DRB1*04:18, DRB1*04:19, DRB1*04:20, DRB1*04:21, DRB1*04:22, DRB1*04:23,
    DRB1*04:24, DRB1*04:25, DRB1*04:26, DRB1*04:27, DRB1*04:28, DRB1*04:29, DRB1*04:30, DRB1*04:31, DRB1*04:32,
    DRB1*04:33, DRB1*04:34, DRB1*04:35, DRB1*04:36, DRB1*04:37, DRB1*04:38, DRB1*04:39, DRB1*04:40, DRB1*04:41,
    DRB1*04:42, DRB1*04:43, DRB1*04:44, DRB1*04:45, DRB1*04:46, DRB1*04:47, DRB1*04:48, DRB1*04:49, DRB1*04:50,
    DRB1*04:51, DRB1*04:52, DRB1*04:53, DRB1*04:54, DRB1*04:55, DRB1*04:56, DRB1*04:57, DRB1*04:58, DRB1*04:59,
    DRB1*04:60, DRB1*04:61, DRB1*04:62, DRB1*04:63, DRB1*04:64, DRB1*04:65, DRB1*04:66, DRB1*04:67, DRB1*04:68,
    DRB1*04:69, DRB1*04:70, DRB1*04:71, DRB1*04:72, DRB1*04:73, DRB1*04:74, DRB1*04:75, DRB1*04:76, DRB1*04:77 and
    DRB1*04:78. The sequence shown is that of DRB1*04:01
    Polymorphism: The following alleles of DRB1-7 are known: DRB1*07:01, DRB1*07:03, DRB1*07:04, DRB1*07:05, DRB1*07:06,
    DRB1*07:07, DRB1*07:08, DRB1*07:09, DRB1*07:11, DRB1*07:12, DRB1*07:13, DRB1*07:14, DRB1*07:15, DRB1*07:16 and
    DRB1*07:17. The sequence shown is that of DRB1*07:01
    Polymorphism: Allele DRB1*07:01 is associated with persistent hepatitis C virus (HCV) infections [MIM:609532]
    Polymorphism: The following alleles of DRB1-8 are known: DRB1*08:01 (Dw8.1), DRB1*08:02 (Dw8.2; DRB1L), DRB1*08:03
    (Dw8.3); DRB1*08:04; DRB1*08:05, DRB1*08:06, DRB1*08:07, DRB1*08:08, DRB1*08:09, DRB1*08:10, DRB1*08:11, DRB1*08:12,
    DRB1*08:13, DRB1*08:14, DRB1*08:15, DRB1*08:16, DRB1*08:17, DRB1*08:18, DRB1*08:19, DRB1*08:20, DRB1*08:21,
    DRB1*08:22, DRB1*08:23, DRB1*08:24, DRB1*08:25, DRB1*08:26, DRB1*08:27, DRB1*08:28, DRB1*08:29, DRB1*08:30,
    DRB1*08:31, DRB1*08:32, DRB1*08:33, DRB1*08:34, DRB1*08:35 and DRB1*08:36. The sequence shown is that of DRB1*08:01
    Polymorphism: The following alleles of DRB1-9 are known: DRB1*09:01, DRB1*09:02, DRB1*09:03, DRB1*09:04, DRB1*09:05,
    DRB1*09:06, DRB1*09:07 and DRB1*09:08. The sequence shown is that of DRB1*09:01
    Polymorphism: The following alleles of DRB1-10 are known: DRB1*10:01; DRB1*10:02 and DRB1*10:03. The sequence shown is
    that of DRB1*10:01
    Polymorphism: The following alleles of DRB1-11 are known: DRB1*11:01, DRB1*11:03, DRB1*11:04, DRB1*11:05, DRB1*11:06,
    DRB1*11:07, DRB1*11:08, DRB1*11:09, DRB1*11:10, DRB1*11:11, DRB1*11:12, DRB1*11:13, DRB1*11:14, DRB1*11:15,
    DRB1*11:16, DRB1*11:17, DRB1*11:18, DRB1*11:19, DRB1*11:20, DRB1*11:21, DRB1*11:22, DRB1*11:23, DRB1*11:24,
    DRB1*11:25, DRB1*11:26, DRB1*11:27, DRB1*11:28, DRB1*11:29, DRB1*11:30, DRB1*11:31, DRB1*11:32, DRB1*11:33,
    DRB1*11:34, DRB1*11:35, DRB1*11:36, DRB1*11:37, DRB1*11:38, DRB1*11:39, DRB1*11:40, DRB1*11:41, DRB1*11:42,
    DRB1*11:43, DRB1*11:44, DRB1*11:45, DRB1*11:46, DRB1*11:47, DRB1*11:48, DRB1*11:49, DRB1*11:50, DRB1*11:51,
    DRB1*11:52, DRB1*11:53, DRB1*11:54, DRB1*11:55, DRB1*11:56, DRB1*11:57, DRB1*11:58, DRB1*11:59, DRB1*11:60,
    DRB1*11:61, DRB1*11:62, DRB1*11:63, DRB1*11:64, DRB1*11:65, DRB1*11:66, DRB1*11:67, DRB1*11:68, DRB1*11:69, DRB1*11:70
    and DRB1*11:72. The sequence shown is that of DRB1*11:01
    Polymorphism: Allele DRB1*11:01 is associated with self-limiting hepatitis C virus (HCV) infections [MIM:609532]
    Polymorphism: The following alleles of DRB1-12 are known: DRB1*12:01, DRB1*12:02, DRB1*12:03, DRB1*12:04, DRB1*12:05,
    DRB1*12:06, DRB1*12:07, DRB1*12:08, DRB1*12:09, DRB1*12:10, DRB1*12:11, DRB1*12:12, DRB1*12:13, DRB1*12:14,
    DRB1*12:15, DRB1*12:16, DRB1*12:17, DRB1*12:18 and DRB1*12:19. The sequence shown is that of DRB1*12:01
    Polymorphism: The following alleles of DRB1-13 are known: DRB1*13:01, DRB1*13:02, DRB1*13:03, DRB1*13:04, DRB1*13:05,
    DRB1*13:06, DRB1*13:07, DRB1*13:08, DRB1*13:09, DRB1*13:10, DRB1*13:11, DRB1*13:12, DRB1*13:13, DRB1*13:14,
    DRB1*13:15, DRB1*13:16, DRB1*13:17, DRB1*13:18, DRB1*13:19, DRB1*13:20, DRB1*13:21, DRB1*13:22, DRB1*13:23,
    DRB1*13:24, DRB1*13:25, DRB1*13:26, DRB1*13:27, DRB1*13:28, DRB1*13:29, DRB1*13:30, DRB1*13:31, DRB1*13:32,
    DRB1*13:33, DRB1*13:34, DRB1*13:35, DRB1*13:36, DRB1*13:37, DRB1*13:38, DRB1*13:39, DRB1*13:40, DRB1*13:41,
    DRB1*13:42, DRB1*13:43, DRB1*13:44, DRB1*13:45, DRB1*13:46, DRB1*13:47, DRB1*13:48, DRB1*13:49, DRB1*13:50,
    DRB1*13:51, DRB1*13:52, DRB1*13:53, DRB1*13:54, DRB1*13:55, DRB1*13:56, DRB1*13:57, DRB1*13:58, DRB1*13:59,
    DRB1*13:60, DRB1*13:61, DRB1*13:62, DRB1*13:63, DRB1*13:64, DRB1*13:65, DRB1*13:66, DRB1*13:67, DRB1*13:68,
    DRB1*13:69, DRB1*13:70, DRB1*13:71, DRB1*13:72, DRB1*13:73, DRB1*13:74, DRB1*13:75, DRB1*13:76, DRB1*13:77,
    DRB1*13:78, DRB1*13:79, DRB1*13:80, DRB1*13:81, DRB1*13:82, DRB1*13:83, DRB1*13:84, DRB1*13:85, DRB1*13:86, DRB1*13:87
    and DRB1*13:88. The sequence shown is that of DRB1*13:01
    Polymorphism: The following alleles of DRB1-14 are known: DRB1*14:01, DRB1*14:02, DRB1*14:03, DRB1*14:04, DRB1*14:05,
    DRB1*14:06, DRB1*14:07, DRB1*14:08, DRB1*14:09, DRB1*14:10, DRB1*14:11, DRB1*14:12, DRB1*14:13, DRB1*14:14,
    DRB1*14:15, DRB1*14:16, DRB1*14:17, DRB1*14:18, DRB1*14:19, DRB1*14:20, DRB1*14:21, DRB1*14:22, DRB1*14:23,
    DRB1*14:24, DRB1*14:25, DRB1*14:26, DRB1*14:27, DRB1*14:28, DRB1*14:29, DRB1*14:30, DRB1*14:31, DRB1*14:32,
    DRB1*14:33, DRB1*14:34, DRB1*14:35, DRB1*14:36, DRB1*14:37, DRB1*14:38, DRB1*14:39, DRB1*14:40, DRB1*14:41,
    DRB1*14:42, DRB1*14:43, DRB1*14:44, DRB1*14:45, DRB1*14:46, DRB1*14:47, DRB1*14:48, DRB1*14:49, DRB1*14:50,
    DRB1*14:51, DRB1*14:52, DRB1*14:53, DRB1*14:54, DRB1*14:55, DRB1*14:56, DRB1*14:57, DRB1*14:58, DRB1*14:59,
    DRB1*14:60, DRB1*14:61, DRB1*14:62, DRB1*14:63, DRB1*14:64, DRB1*14:65, DRB1*14:67, DRB1*14:68, DRB1*14:69,
    DRB1*14:70, DRB1*14:71, DRB1*14:72, DRB1*14:73, DRB1*14:74, DRB1*14:75, DRB1*14:76, DRB1*14:77, DRB1*14:78,
    DRB1*14:79, DRB1*14:80, DRB1*14:81, DRB1*14:82, DRB1*14:83, DRB1*14:84 and DRB1*14:85. The sequence shown is that of
    DRB1*14:01
    Polymorphism: The following alleles of DRB1-15 are known: DRB1*15:01, DRB1*15:02, DRB1*15:03, DRB1*15:04, DRB1*15:05,
    DRB1*15:06, DRB1*15:07, DRB1*15:08, DRB1*15:09, DRB1*15:10, DRB1*15:11, DRB1*15:12, DRB1*15:13, DRB1*15:14,
    DRB1*15:15, DRB1*15:16, DRB1*15:18, DRB1*15:19, DRB1*15:20, DRB1*15:21, DRB1*15:22, DRB1*15:23, DRB1*15:24,
    DRB1*15:25, DRB1*15:26, DRB1*15:27, DRB1*15:28, DRB1*15:29, DRB1*15:30, DRB1*15:31 and DRB1*15:32. The sequence shown
    is that of DRB1*15:01
    Polymorphism: The following alleles of DRB1-16 are known: DRB1*16:01; DRB1*16:02; DRB1*16:03; DRB1*16:04; DRB1*16:05;
    DRB1*16:07; DRB1*16:08; DRB1*16:09; DRB1*16:10; DRB1*16:11 and DRB1*16:12. The sequence shown is that of DRB1*16:02


    10/3606 NCBI SNPs in HLA-DRB1 are shown (see all 3606)
    Genomic DataTranscription Related DataAllele Frequencies
    SNP IDValidChr 6 posSequenceRecsAA
    Chg
    TypeMoreRecsAllele
    freq
    PopTotal
    sample
    More
    ----------
    rs17291,2
    C32546629(+) TACGGA/GTTAGG 1 -- ut310--------
    rs17301,2
    C32546674(+) GCCATC/TAATGC 1 -- ut310--------
    rs17321,2
    C,F,32546711(+) TGAGGC/AAGCCA 1 -- ut311Minor allele frequency- A:0.36MN 184
    rs123631,2
    C32546805(-) GCTTTC/TCTGCT 1 -- ut31 ese31Minor allele frequency- T:0.00MN 6
    rs7018311,2
    C,F,H32549395(-) AGTGGG/AGAGGT 2 /G ref1 syn15Minor allele frequency- A:0.17NS EA 590
    rs7079541,2
    C,F32549495(-) GAACGA/G/TCCAGG 3 D G V mis1 ref1 ese34MN NA 246
    rs10593621,2
    C,F32548550(-) CCGGGC/TTGTTC 2 L ref1 syn11Minor allele frequency- T:0.25MN 48
    rs10595461,2
    C,F32557552(-) CTGCTC/TCTCTG 1 -- ut51 ese31Minor allele frequency- T:0.21MN 56
    rs10595751,2
    C,32552085(-) CTGGAA/C/GAGATA 3 E D mis1 ref10--------
    rs10595831,2
    --32551997(-) CTGACA/C/GCTGAG 3 T P A mis1 ref10--------
    About this table

    HapMap Linkage Disequilibrium images for HLA-DRB1 (up to first 250kb)
    Structural Variations (Copy Number Variations, Insertions/Deletions, Inversions)
    Database of Genomic Variants (DGV): 22 variations for HLA-DRB1
         15/20 CNVs (see all 20): 7567 69436 37840 69447 69420 4767 4493 64476 3603 69431 69407 69452 81340 69421 93647
         2 Indels: 33807 12831

    Search QIAGEN SeqTarget long-range PCR primers for resequencing for HLA-DRB1 

    (in which this Gene is Involved, According to OMIM, UniProtKB, Novoseek, PharmGKB, Genatlas, GeneTests, Blood group antigen gene mutations by BGMUT, LSDB, HGMD, GAD, HuGE Navigator, and/or TGDB.)
    About This Section

    HLA-DRB1 for disorders           About GeneDecksing

    OMIM: 142857

    UniProtKB/Swiss-Prot: 2B1G_HUMAN, Q29974

  • Genetic variation in HLA-DRB1 is a cause of susceptibility to sarcoidosis type 1 (SS1) [MIM:181000].
  • Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in
    involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen,
    eyes and other organs may be involved

    10/53 Novoseek disease relationships for HLA-DRB1 gene (see all 53)

    Disease   -log (P-Val)   Hits   PubMed IDs for Articles with Shared Sentences (# sentences)
    rheumatoid arthritis 66.3 64 1416553 (3), 16277691 (2), 16385499 (2), 10765919 (2) (see all 44)
    genetic susceptibility 65.2 8 17055211 (1), 17047287 (1), 17309132 (1), 18004301 (1) (see all 8)
    polymyalgia rheumatica 58.1 10 10225816 (2), 8147928 (2), 9458210 (2), 15305244 (2) (see all 5)
    diabetes mellitus insulin-dependent 50.2 2 10680451 (1), 7817375 (1)
    autoimmune diseases 49.3 5 16362107 (1), 19117368 (1), 16198136 (1), 1617108 (1) (see all 5)
    vogt-koyanagi-harada disease 46.6 2 7906684 (1), 15603876 (1)
    autoimmunity 44.1 4 16385499 (1), 17987563 (1), 15120192 (1), 8675578 (1)
    hepatitis autoimmune 44 3 1350267 (2), 9672174 (1)
    pemphigus foliaceus 36.9 1 9027963 (1)
    diabetes autoimmune 35.6 2 10333055 (1), 18279373 (1)
    About this table

    1 PharmGKB disease relationship for HLA-DRB1 gene
    Disease PharmGKB Relations PubMed IDs for articles supporting these relationships
    Anemia, AplasticPD  9277043
    About this table

    Locus Specific Mutation Databases (LSDB): HLA-DRB1
    Human Gene Mutation Database (HGMD): HLA-DRB1
    Genetic Association Database (GAD): HLA-DRB1
    Human Genome Epidemiology (HuGE) Navigator: HLA-DRB1 (1758 documents)

    Export disorders and mutations for HLA-DRB1 gene to outside databases

    (Possibly Related Articles in Doctor's Guide)
    About This Section

    (in PubMed. Associations of this gene to articles via 1Entrez Gene, 2UniProtKB/Swiss-Prot, 3HGNC, 4GAD, 5PharmGKB, 6UniProtKB/TrEMBL, and/or 7Novoseek)
    About This Section

    10/2282 PubMed articles for HLA-DRB1 gene, integrated from 7 sources (see all 2282):
    (articles sorted by number of sources associating them with HLA-DRB1)
    1. [Determination of HLA-DRB1 gene polymorphism in Luoba ethnic group of Tibet] (PubMed id 15898419)1, 4, 7 Kang L.L....Li S.B. (2005)
    2. Influence of HLA-DRB1 and TNF microsatellite polymorphisms on the expression of extraarticular manifestations in rheumatoid arthritis patients from northwest Spain. (PubMed id 11791643)1, 4, 7 Mattey D.L....Ollier W.E. (2001)
    3. [Possible association between HLA-HRB1 and DQB1 genes frequency and susceptibility or resistance to Helicobacter pylori infection in Kunming Yi ethnic group children] (PubMed id 15833172)1, 4, 7 Huang Y.K....Zhou L.F. (2005)
    4. [Association of HLA-A, B, and DR haplotypes with genotype in Chinese children with systemic lupus erythematosus] (PubMed id 14748996)1, 4, 7 Li C.F....Jiang Z.F. (2003)
    5. [Polymorphism of length of tetranucleotide repeat from the 5'-side from the myelin basic protein gene in multiple sclerosis in Russians] (PubMed id 14714495)1, 4, 7 Andreevskii T.V....Favorova O.O. (2003)
    6. HLA-DRB1 and HLA-DQB1 polymorphisms in Pacific Islands populations. (PubMed id 12144623)1, 4, 7 Velickovic Z.M....Carter J.M. (2002)
    7. Collagenase-1 (MMP-1) and HLA-DRB1 gene polymorphisms in rheumatoid arthritis: a prospective longitudinal study. (PubMed id 11824952)1, 4, 7 Constantin A....Cantagrel A. (2002)
    8. Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis. (PubMed id 16385499)1, 4, 7 Burkhardt H....Reis A. (2006)
    9. [Polymorphism of HLA-A,-B and DRB1 in Han population of Shanxi province] (PubMed id 16215957)1, 4, 7 Lan T....Wang G.Q. (2005)
    10. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. (PubMed id 16277691)1, 4, 7 Turesson C....Matteson E.L. (2005)

    (in PubMed, OMIM, and NCBI Bookshelf)
    About This Section
     ANDOR
    Aliases
    Disorders
    Free Text  

      Query String
    PubMed
    OMIM
    NCBI Bookshelf
      (Note: In FireFox, select the above section and copy using Ctrl-C)

    (According to Entrez Gene, HGNC, AceView, euGenes, Ensembl, miRBase, ECgene, Kegg, and/or H-InvDB)
    About This Section
    Entrez Gene: 3123 HGNC: 4948 AceView: HLA-DRB1.1 Ensembl:ENSG00000196126 euGenes: HUgn3123
    ECgene: HLA-DRB1 Kegg: 3123 H-InvDB: HLA-DRB1

    (According to HUGE)
    About This Section
      --

    (According to ATLAS, HORDE, IMGT, MTDB, LEIDEN, UniProtKB/Swiss-Prot, and/or UniProtKB/TrEMBL,
    Wikipedia and/or GeneReviews via UniProtKB/Swiss-Prot)
    About This Section
      --

    (Patent information from GeneIP,
    Licensable technologies from WIS Yeda, Salk, Tufts,
    IP news from XenneX, Inc.)
    About This Section
    Patent Information for HLA-DRB1 gene:
    Search GeneIP for patents involving HLA-DRB1

    GeneCards and IP:
    Japan Patent Office Licenses GeneCards     European Patent Office Licenses GeneCards     Improving the IP Search



    (Antibodies, recombinant proteins, and assays by Millipore, Sigma-Aldrich, R&D Systems, Qiagen, GenScript, Cell Signaling Technology, SABiosciences, Novus Biologicals, Epitomics, ProSpec, Uscn,
    Clones available from Millipore, Sigma-Aldrich, OriGene, GenScript, Sino Biological, PCR Arrays from SABiosciences, Drugs and/or compounds by Sigma-Aldrich, Tocris Bioscience, and/or Enzo Life Sciences)
    About This Section

     Millipore Custom Antibody & Bulk Services
     Millipore Preclinical / Clinical Development Services
     Millipore Immunoassay Services
     Millipore Target Screening & Profiling Services

     Predesigned and custom siRNAs for HLA-DRB1 Antibodies for HLA-DRB1
     Explore super-pooled esiRNAs Browse proteins at Sigma-Aldrich
     Lentivirus-delivered shRNAs for HLA-DRB1 microRNA Mimics for HLA-DRB1
     "Your Favorite Gene" Pathways and Molecular Interaction Networks Browse Nano Scale siRNA at Sigma-Aldrich
     Browse iPSC Reprogramming Factors at Sigma-Aldrich Browse small molecules at Sigma-Aldrich
     Browse FLAG tag genes at Sigma-Aldrich Browse ELISAs at Sigma-Aldrich
     Browse microRNA Target Validation Systems at Sigma-Aldrich Browse CompoZr Knockout ZFN at Sigma-Aldrich
    feedback
      
     Antibodies   Cell Culture Products  
     ELISAs   Flow Cytometry Kits  
     Primer Pairs   Kinase Activity Assays/Reagents  
     ELISpot Kits/Development Modules   TFB/Immunoprecipitation Assays  
     Apoptosis Detection Kits/Reagents   Protease Activity Assays/Reagents  
     DNA Damage/Repair Kits/Reagents   Multiplex/Array Assay Kits/Reagents  
     Cell Selection/Detection Kits/Reagents   ELISA/Assay Development Kits/Reagents  
     Phosphatase Activity Assays/Reagents   Recombinant/Natural Proteins  
     Tagged/untagged cDNA clones
     Validated SYBR primer pairs
     Purified proteins from HEK293T cells
     Lysates
     Western blot validated antibodies
     shRNA in GFP-retroviral vector
     siRNA
     Custom Immunoassay Development
     Fluorogenic Cell Assay Kits
     miRNA Primers for qPCR Assays
     3' UTR Clones for miRNA Target Studies
     miRNA Expression Plasmids

     
     
     QIAGEN Custom miScript Target Protector blocks miRNA-binding site of HLA-DRB1
     Search QIAGEN SeqTarget long-range PCR primers for resequencing for HLA-DRB1
     QIAGEN PyroMark CpG Assay predesigned Pyrosequencing DNA Methylation assays
     QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing of HLA-DRB1
     GenScript Custom Purified and Recombinant Proteins Services for HLA-DRB1 GenScript Custom cDNA clones with any tag delivered in your preferred vector Services for HLA-DRB1
     GenScript Custom Assay Services for HLA-DRB1 GenScript Custom Superior Antibodies Services for HLA-DRB1
     GenScript Custom overexpressing Cell Line Services for HLA-DRB1 CloneReady with Over 120,000 Genes
     Gene Synthesis: Any Gene in Any Vector Vector-based siRNA and miRNA, Ready for Transfection
     Gene Mutant Library, Variants up to 10^11 Plasmid Preparation
     Custom Peptide Services
     Search for Antibodies & Assays

     Regulatory tfbs in HLA-DRB1 promoter
     Search Chromatin IP Primers for HLA-DRB1
     RT2 qPCR Primer Assay for HLA-DRB1
     GNC Network for HLA-DRB1
     Search for Assays for microRNAs that regulate HLA-DRB1
     SABiosciences PCR Arrays including HLA-DRB1
     Search Tocris compounds for HLA-DRB1
     Browse Sino Biological Proteins and Antibodies
     Browse Sino Biological cDNA Clones
     Antibodies/Proteins Production Services
     Rabbit Monoclonal Antibody Platform
     Bulk Purchasing
     Search www.enzolifesciences.com for proteins, assays, substrates, inhibitors & antibodies
     Novus Tissue Slides
     Antibodies for HLA-DRB1
     Lysates for HLA-DRB1
     Antibodies for HLA-DRB1
     Browse ProSpec Recombinant Proteins

     ELISAs and CLIAs for HLA-DRB1
           

    GeneCards Homepage - Last full update: 31 Dec 2010 - Incremental updates: 10 Jan 2011 , 10 Jan 2011

    View Random Gene

    Category
    GIFtS Group
    The GeneCards human gene database gene index: 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 


    Developed at the Crown Human Genome Center, Department of Molecular Genetics, the Weizmann Institute of Science

    HLA-DRB1 gene at Home site.
    hostname: www-ab3 db genecards_305 index build: 81e solr: 1.4